CDK1 and breast cancer: Compounds acting as CDK-1 and/or PARP-1 inhibitors are effective in causing cell death in BC but not in normal cells through a selective synthetic lethality mechanism; the treatment with mixed therapy by means of CDK-1 and PARP-1 inhibitors resulted in a radical cell growth reduction.